

This is to certify that

Dr. Muhammad Parenrengi

has reviewed a manuscript entitled:

"Atypical Teratoid/Rhabdoid Tumor of the Sellar Region in an Adult Male: A Case report" (2022-11-19)

For

Surgical Neurology International

We appreciate the contribution.



Dr. Nancy Epstein
(Editor-in-Chief)



Atypical Teratoid/Rhabdoid Tumor of the Sellar Region in an Adult Male: A Case report

Abstract

Background:

Atypical teratoid/rhabdoid tumor (AT/RT) is a rare, fast growing, aggressive tumor, that is almost exclusively seen in pediatric population. It has a poor prognosis despite aggressive treatment. Nonetheless, there are over 50 cases of AT/RT in adults up to this date. Sellar occurrence is rarely reported, with only 23 cases reported in the literature. All of those cases were female, which raised the question of whether sellar AT/RT is a sex-related disease.

Case presentation:

We report a case of sellar atypical teratoid/rhabdoid tumor (AT/RT) in a 35-year-old male that posed a unique clinical and diagnostic challenge. To the best of our knowledge, this is the third case of male patient with sellar AT/RT in the world.

Commented [1]: There is no clinical information about the patient, especially his chief complaint. What is unique about the clinical condition?

Conclusion:

Sellar AT/R is extremely rare in an adult male. We report the third case in the literature. Thus disputing the belief that it is a female-exclusive disease. Nonetheless, Sellar AT/RT poses a unique entity that mandates further research and understanding. The rarity and the complexity of managing such cases mandate sharing them whenever possible.

Introduction:

Atypical teratoid/rhabdoid tumor (AT/RT) was first described in 1985. (1) It is a rare, fast growing, aggressive tumor, that is mostly exclusively seen in pediatric population with poor prognosis despite aggressive treatment. (2) It constitutes 1-2% of all pediatric CNS tumors. (3) Nonetheless, there are over 50 cases of AT/RT in adults up to this date. Horn et al were the first to report AT/RT in adult patient in 1992. (4) AT/RT can occur anywhere in CNS. As all CNS tumors, clinical presentation varies with tumor location. Sellar occurrence is rarely reported, with only 23 cases reported in the literature. (5) interestingly, almost all adult patients with sellar AT/RT were female, which raised the question of it being a sex-related disease.

Hereby, We report the third case of sellar atypical teratoid/rhabdoid tumor (AT/RT) in a 35-year-old male that posed a unique clinical and diagnostic challenge.

Commented [2]: What is new in this paper? There is a case series with the clinical features, radiologic findings, pathological characteristics, treatment, and outcomes of a series of five adult sellar regions AT/RT.

Case presentation:

A 32 year old male, who is a known case of schizophrenia and obsessive compulsive disorder, brought to our emergency department by his father as he was complaining of headache, high grade fever, and vomiting for 4 days. Also, he had left eye redness and greenish discharge. the patient became unresponsive and dyspneic shortly after presentation, so he was intubated and stabilized. Later, the patient developed generalized tonic clonic seizure. On examination, his Glasgow Coma Scale (GCS) was 7/15, his pupils were equal and reactive. No signs of meningism, clonus, or further abnormal movement were

Commented [3]: What is the unique clinical condition mentioned?

observed. Computed tomography (CT) of the brain (Figure. 1) showed sellar mass with suprasellar extension compressing the chiasmatic structures asymmetrically right more than left. The lesion invaded the left cavernous sinus and intruded the anterior aspect of the sellar floor. The lesion was considered as incidental finding, and the patient was worked up as a case of meningoencephalitis and started on antibiotics. Septic workup including cerebrospinal fluid (CSF) examination was negative. Hormonal profile showed panhypopituitarism, thus hormonal replacement was started. The patient developed pulmonary embolism on the third day of admission, and he was treated accordingly.

Commented [4]: There is no CT Scan imaging.

Commented [5]: What is the result of the cranial nerve examination for the cavernous sinus invasion?

Commented [6]: What is the hormonal laboratory value? What hormonal drugs are given?

Once his condition stabilized, Magnetic Resonance image (MRI) of the brain (figure. 2) demonstrated a sellar lesion with suprasellar extension and extension inferiorly to the sphenoid sinus. The lesion was hypointense on T1 with peripheral hyperintensity and intensely hypointense on T2 and gradient echo sequences. Post gadolinium study showed the lesion to be enhancing in its periphery only with mild heterogeneous enhancement in the center. The lesion invaded the left cavernous sinus with significant compression of the optic chiasm. GRE study showed presence of small bleed in the dependent part of the lateral ventricle, which raised the suspicion of apoplexy. The patient was on hormonal replacement, antibiotic coverage, and appropriate anti-epileptic medications, yet with no improvement in terms of level of consciousness or fever. On the third week of admission, the patient developed unequal pupils. CT brain showed enlargement of the hemorrhagic sellar and suprasellar mass. The patient underwent trans-sphenoidal endoscopic debulking for sellar/suprasellar lesion. Postoperatively, the patient's neurological status remained unchanged.

Commented [7]: What are the N. II examination results? N. II visual field test is performed?

Commented [8]: There is no CT Scan information.

Commented [9]: What is the reason for performing the procedure with a trans-sphenoidal endoscopic?

Commented [10]: What is GCS score before surgery? And the condition after surgery?

Histopathological examination (Figure 3) showed a highly hemorrhagic and necrotic neoplasm. The residual viable tumor showed focally papillary architecture and was composed of cells with round to ovoid nuclei, prominent nucleoli and scant cytoplasm. The cells were negative for synaptophysin, prolactin, and transcription factor Pit1. The cells showed loss of expression of INI-1, which was consistent with Atypical Teratoid Rhabdoid Tumor. Immunohistochemical stains showed positivity for Epithelial membrane antigen (EMA), and faint patchy positivity for CD56 and had a Ki67 proliferation index focally elevated (5-10%). Pituitary hormones, including prolactin, GH, TSH, ACTH, FSH, and LH, were negative.

Commented [11]: What is further management expected from the author?

Commented [12]: What is the reason for deteriorating?

Commented [13]: There is no information about this imaging.

The patient was referred to oncology service for further management. Yet, two weeks after surgery, the patient deteriorated in term of level of consciousness. His GCS was 3/15, with no brainstem reflexes. CT of the brain showed progressive intraventricular hemorrhage and hydrocephalus, with diffuse cerebral edema. External ventricular drain was inserted, but with no improvement clinically. The patient was declared brain dead, and he died 3 months after the initial presentation.

Discussion:

Commented [14]: There is no clear information why this report has the unique clinical and diagnostic challenges.

AT/RT is prototypically an aggressive tumor of infancy, constituting 10% of CNS tumors in this age group. (6,7) AT/RT is defined by inactivation of SMARCB1, or SMARCA4 in rare cases. (7) Occurrence of AT/RT in adult is extremely rare, with less than 60 cases reported in the literature up to date. (5) Distinguished from pediatric AT/RT, Adult-onset AT/RT is typically supratentorial, with slight predilection for mid-line structures.(8) Moreover, many cases reported long-term survival which may indicate more favorable outcome than pediatric cases. (9) Sellar occurrence is exclusively reported in adult cases. Reported findings suggest that

sellar AT/RT may represent a unique subgroup with distinctive clinical, pathological, and genetic features.

Sellar AT/RT show strong females predominance.(10) Up to our knowledge, This case is one of only 3 Sellar AT/RT in male patients. (8,11) The underlying mechanism is still unknown, as there was no deviation to certain age group, or significant relation to hormonal profile. (12) Presentation of sellar AT/RT is not specific to the pathology, most patient presented with visual symptoms.

Imaging findings are variable and nonspecific. AT/RT have iso-intense to hyperintense T2 signal, and enhance with contrast administration. (7) Histologically, these tumors are heterogenous lesions, composed of bizarre eosinophilic cells with eccentric nuclei, and mixed features of rhabdoid, neuroectodermal, and mesenchymal cells. (7)

Loss of INI1 staining due to SMARCB1 mutations is considered sufficient for diagnosis, which appears to be the most consistent mutation in Adult AT/RR. (7) Alternatively, inactivation of BRG1 due to mutation of SMARCA4 is rarely recognized if INI1 expression is intact. (13) Nakata et al studied the molecular status of the INI1/SMARCB1 gene in a series of adult sellar AT/RT. (12) Compound heterozygous mutations were present in 57% of cases of sellar AT/RT, in contrast to pediatric AT/RT where such mutations are rare. (12,14) In addition, there was a significant difference in their prevalence between sellar AT/RT and conventional AT/RT. On the other hand, homozygous deletion of INI1 gene was not reported in sellar AT/RT cases despite being a common mutation in typical AT/RT. (6) Those observations may indicate that sellar AT/RT represent unique variant of AT/RT with different demographical, molecular, and clinical characteristics.

Sellar AT/RT cases appear to have more favorable outcome than conventional AT/RT. (5,15) The estimated median overall survival of sellar AT/RT is 30 months, with 1-year survival of 76.7%, compared to 11 to 14 months for conventional AT/RT. (11,16) Achieving gross total resection was a determinant for favorable outcome in pediatric. (17) Yet, there was no survival benefit seen for gross total resection in adult AT/RT. (18) Receiving chemotherapy and radiotherapy was significantly associated with better survival compared with radiotherapy only or no adjuvant therapy at all. (5,18) Adjuvant therapy protocols varied drastically in the literature, with data mostly being extrapolated from pediatric literature. Slavc et al (9) developed an intensive 9-week course of a dose-dense regimen, augmented with intrathecal therapy followed by high-dose chemotherapy and radiotherapy for pediatric AT/RT. This protocol achieved a 5-year overall survival rate of 100% and a 5-year event-free survival rate of 88.9% in nine cases of AT/RT with and without disseminated disease.

Sellar AT/R is extremely rare in an adult male. We report the third case in the literature. Thus disputing the belief that it is a female-exclusive disease. Nonetheless, Sellar AT/RT poses a unique entity that mandates further research and understanding.

Commented [15]: What's the conclusion? There is no conclusion heading. What do you expect from this report?

ACKNOWLEDGEMENTS: None.

Reference:

1. Almalki MH, Alrogi A, Al-Rabie A, Al-Dandan S, Altwairgi A, Orz Y. Atypical Teratoid/Rhabdoid Tumor of the Sellar Region in an Adult With Long Survival: Case Report and Review of the Literature. *J Clin Med Res* [Internet]. 2017 [cited 2020 Mar 30];9(3):216–20. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/28179970><http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC5289142><http://www.jocmr.org/index.php/JOCMR/article/view/2922>
2. Biegel JA. Molecular genetics of atypical teratoid/rhabdoid tumor. Vol. 20, *Neurosurgical focus. Neurosurg Focus*; 2006.
3. Burger PC, Yu IT, Tihan T, Friedman HS, Strother DR, Kepner JL, et al. Atypical teratoid/rhabdoid tumor of the central nervous system: A highly malignant tumor of infancy and childhood frequently mistaken for medulloblastoma: A Pediatric Oncology Group study. *Am J Surg Pathol*. 1998 Sep;22(9):1083–92.
4. Chan V, Marro A, Max Findlay J, Schmitt LM, Das S. A systematic review of atypical teratoid rhabdoid tumor in adults. Vol. 8, *Frontiers in Oncology. Frontiers Media S.A.*; 2018.
5. Dardis C, Yeo J, Milton K, Ashby LS, Smith KA, Mehta S, et al. Atypical teratoid rhabdoid tumor: Two case reports and an analysis of adult cases with implications for pathophysiology and treatment. *Front Neurol*. 2017 Jun 20;8(JUN).
6. Horn M, Schlote W, Lerch KD, Steudel WI, Harms D, Thomas E. Malignant rhabdoid tumor: primary intracranial manifestation in an adult. *Acta Neuropathol*. 1992 Jul;83(4):445–8.
7. Isikay I, Hanalioglu S, Basar I, Narin F, Bilginer B. Survival benefit with gross total resection and adjuvant radiotherapy in childhood atypical teratoid/rhabdoid tumors: Results of a single-center cohort of 27 cases. *Turk Neurosurg* [Internet]. 2019 [cited 2021 Jun 7];29(5):689–97. Available from: <https://pubmed.ncbi.nlm.nih.gov/30875078/>
8. Liu F, Fan S, Tang X, Fan S, Zhou L. Adult Sellar Region Atypical Teratoid/Rhabdoid Tumor: A Retrospective Study and Literature Review. *Front Neurol* [Internet]. 2020 Dec 15 [cited 2021 Jun 7];11:604612. Available from: </pmc/articles/PMC7769810/>
9. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK. The 2007 WHO classification of tumours of the central nervous system. International Agency for Research on Cancer (IARC) 69372 Lyon Cedex 08, France; 2016.
10. Montgomery P, Kuhn JP, Berger PE. Rhabdoid tumor of the kidney: A case report. *Urol Radiol A J diagnostic imaging*. 1985;7(1):42–4.
11. Nakata S, Nobusawa S, Hirose T, Ito S, Inoshita N, Ichi S, et al. Sellar Atypical Teratoid/Rhabdoid Tumor (AT/RT). *Am J Surg Pathol*. 2017 Jul;41(7):932–40.
12. Nishikawa A, Ogiwara T, Nagm A, Sano K, Okada M, Chiba A, et al. Atypical teratoid/rhabdoid tumor of the sellar region in adult women: Is it a sex-related disease? Vol. 49, *Journal of Clinical Neuroscience. Churchill Livingstone*; 2018. p. 16–21
13. Paolini MA, Kipp BR, Sukov WR, Jenkins SM, Fritcher EGB, Aranda D, et al. Sellar Region Atypical Teratoid/Rhabdoid Tumors in Adults: Clinicopathological

Commented [16]: Reference are not uniform and many are incomplete.

Characterization of Five Cases and Review of the Literature. Available from: <https://academic.oup.com/jnen/article/77/12/1115/5116242>

14. Rickert CH, Paulus W. Epidemiology of central nervous system tumors in childhood and adolescence based on the new WHO classification. *Child's Nerv Syst.* 2001;17(9):503–11.
15. Schneppenheim R, Frühwald MC, Gesk S, Hasselblatt M, Jeibmann A, Kordes U, et al. Germline Nonsense Mutation and Somatic Inactivation of SMARCA4/BRG1 in a Family with Rhabdoid Tumor Predisposition Syndrome. *Am J Hum Genet.* 2010 Feb;86(2):279–84.
16. Schrey D, Carceller Lechón F, Malietzis G, Moreno L, Dufour C, Chi S, et al. Multimodal therapy in children and adolescents with newly diagnosed atypical teratoid rhabdoid tumor: individual pooled data analysis and review of the literature. *J Neurooncol.* 2016 Jan;126(1):81–90.
17. Slavc I, Chocholous M, Leiss U, Haberler C, Peyrl A, Azizi AA, et al. Atypical teratoid rhabdoid tumor: improved long-term survival with an intensive multimodal therapy and delayed radiotherapy. *The Medical University of Vienna Experience 1992-2012.* *Cancer Med [Internet].* 2014 Feb 1 [cited 2020 Nov 10];3(1):91–100. Available from: [/pmc/articles/PMC3930393/?report=abstract](https://pubmed.ncbi.nlm.nih.gov/24711111/)
18. Torchia J, Golbourn B, Feng S, Ho KC, Sin-Chan P, Vasiljevic A, et al. Integrated (epi)-Genomic Analyses Identify Subgroup-Specific Therapeutic Targets in CNS Rhabdoid Tumors. *Cancer Cell.* 2016 Dec;30(6):891–908.

Key words:

Atypical teratoid/ rhabdoid tumor, AT/RT, sellar lesion, Inactivation of SMARCB1, SMARCB1

Commented [17]: Inconsistent writing format.




Figure 1: A: MRI brain with contrast showing sellar lesion with suprasellar extension and extension inferiorly to the sphenoid sinus. B: Post gadolinium study showed the lesion to be enhancing in its periphery only with mild heterogeneous enhancement in the center

Commented [18]: 1. The information about images is not clear. Which one is the figure A and B. There is no information about MRI sequences. In the case presentation is written CT scan imaging, but in the figure is MR imaging, which one is true?

2. Please give detail mark using arrow mark the pathology and important anatomy landmark at the figures.




Figure 2: MRI brain with contrast showing Slight interval progression of lesion size with heterogeneous texture/enhancement and ill-defined margins. And development of subacute intraventricular hemorrhage predominantly involving third ventricle.

Commented [19]: 1. There is no information about MRI sequences and which one is figure A and B.
 2. Please give detail mark using arrow mark the pathology and important anatomy landmark at the figures.




Figure 3: Histopathological examination: A: H&E slide shows hemorrhagic and necrotic neoplasm with focal papillary architecture. B: The tumor is composed of cells with round nuclei, prominent nucleoli and scant cytoplasm. C: Immunohistochemical stain (EMA), positive in the tumor cells. D: Immunohistochemical stain (INI-1), loss of expression in the tumor cells and retention in the internal positive controls including endothelial cells. E: (KI67) proliferation index, focally elevated.

Commented [20]: Please mark each image.

Atypical Teratoid/Rhabdoid Tumor of the Sellar Region in an Adult Male: A Case report

Abstract

Background:

Atypical teratoid/rhabdoid tumor (AT/RT) is a rare, fast growing, aggressive tumor, that is almost exclusively seen in pediatric population. It has a poor prognosis despite aggressive treatment. Nonetheless, there are over 50 cases of AT/RT in adults up to this date. Sellar occurrence is rarely reported, with only 23 cases reported in the literature. All of those cases were female, which raised the question of whether sellar AT/RT is a sex-related disease.

Case presentation:

We report a case of sellar atypical teratoid/rhabdoid tumor (AT/RT) in a 35-year-old male that posed a unique clinical and diagnostic challenge. To the best of our knowledge, this is the third case of male patient with sellar AT/RT in the world.

Conclusion:

Sellar AT/R is extremely rare in an adult male. We report the third case in the literature. Thus disputing the belief that it is a female-exclusive disease. Nonetheless, Sellar AT/RT poses a unique entity that mandates further research and understanding. The rarity and the complexity of managing such cases mandate sharing them whenever possible.

Introduction:

Atypical teratoid/rhabdoid tumor (AT/RT) was first described in 1985. (1) It is a rare, fast growing, aggressive tumor, that is mostly exclusively seen in pediatric population with poor prognosis despite aggressive treatment. (2) It constitutes 1-2% of all pediatric CNS tumors. (3) Nonetheless, there are over 50 cases of AT/RT in adults up to this date. Horn et al were the first to report AT/RT in adult patient in 1992. (4) AT/RT can occur anywhere in CNS. As all CNS tumors, clinical presentation varies with tumor location. Sellar occurrence is rarely reported, with only 23 cases reported in the literature. (5) interestingly, almost all adult patients with sellar AT/RT were female, which raised the question of it being a sex-related disease.

Hereby, We report the third case of sellar atypical teratoid/rhabdoid tumor (AT/RT) in a 35-year-old male that posed a unique clinical and diagnostic challenge.

Case presentation:

A 32 year old male, who is a known case of schizophrenia and obsessive compulsive disorder, brought to our emergency department by his father as he was complaining of headache, high grade fever, and vomiting for 4 days. Also, he had left eye redness and greenish discharge. the patient became unresponsive and dyspneic shortly after presentation, so he was intubated and stabilized. Later, the patient developed generalized tonic clonic seizure. On examination, his Glasgow Coma Scale (GCS) was 7/15, his pupils were equal and reactive. No signs of meningism, clonus, or further abnormal movement were

observed. Computed tomography (CT) of the brain (Figure. 1) showed sellar mass with suprasellar extension compressing the chiasmatic structures asymmetrically right more than left. The lesion invaded the left cavernous sinus and intruded the anterior aspect of the sellar floor. The lesion was considered as incidental finding, and the patient was worked up as a case of meningoencephalitis and started on antibiotics. Septic workup including cerebrospinal fluid (CSF) examination was negative. Hormonal profile showed panhypopituitarism, thus hormonal replacement was started. The patient developed pulmonary embolism on the third day of admission, and he was treated accordingly.

Once his condition stabilized, Magnetic Resonance image (MRI) of the brain (figure. 2) demonstrated a sellar lesion with suprasellar extension and extension inferiorly to the sphenoid sinus. The lesion was hypointense on T1 with peripheral hyperintensity and intensely hypointense on T2 and gradient echo sequences. Post gadolinium study showed the lesion to be enhancing in its periphery only with mild heterogeneous enhancement in the center. The lesion invaded the left cavernous sinus with significant compression of the optic chiasm. GRE study showed presence of small bleed in the dependent part of the lateral ventricle, which raised the suspicion of apoplexy. The patient was on hormonal replacement, antibiotic coverage, and appropriate anti-epileptic medications, yet with no improvement in terms of level of consciousness or fever. On the third week of admission, the patient developed unequal pupils. CT brain showed enlargement of the hemorrhagic sellar and suprasellar mass. The patient underwent trans-sphenoidal endoscopic debulking for sellar/suprasellar lesion. Postoperatively, the patient's neurological status remained unchanged.

Histopathological examination (Figure 3) showed a highly hemorrhagic and necrotic neoplasm. The residual viable tumor showed focally papillary architecture and was composed of cells with round to ovoid nuclei, prominent nucleoli and scant cytoplasm. The cells were negative for synaptophysin, prolactin, and transcription factor Pit1. The cells showed loss of expression of INI-1, which was consistent with Atypical Teratoid Rhabdoid Tumor. Immunohistochemical stains showed positivity for Epithelial membrane antigen (EMA), and faint patchy positivity for CD56 and had a Ki67 proliferation index focally elevated (5-10%). Pituitary hormones, including prolactin, GH, TSH, ACTH, FSH, and LH, were negative.

The patient was referred to oncology service for further management. Yet, two weeks after surgery, the patient deteriorated in term of level of consciousness. His GCS was 3/15, with no brainstem reflexes. CT of the brain showed progressive intraventricular hemorrhage and hydrocephalus, with diffuse cerebral edema. External ventricular drain was inserted, but with no improvement clinically. The patient was declared brain dead, and he died 3 months after the initial presentation.

Discussion:

AT/RT is prototypically an aggressive tumor of infancy, constituting 10% of CNS tumors in this age group. (6,7) AT/RT is defined by inactivation of SMARCB1, or SMARCA4 in rare cases. (7) Occurrence of AT/RT in adult is extremely rare, with less than 60 cases reported in the literature up to date. (5) Distinguished from pediatric AT/RT, Adult-onset AT/RT is typically supratentorial, with slight predilection for mid-line structures.(8) Moreover, many cases reported long-term survival which may indicate more favorable outcome than pediatric cases. (9) Sellar occurrence is exclusively reported in adult cases. Reported findings suggest that

sellar AT/RT may represent a unique subgroup with distinctive clinical, pathological, and genetic features.

Sellar AT/RT show strong females predominance.(10) Up to our knowledge, This case is one of only 3 Sellar AT/RT in male patients. (8,11) The underlying mechanism is still unknown, as there was no deviation to certain age group, or significant relation to hormonal profile. (12) Presentation of sellar AT/RT is not specific to the pathology, most patient presented with visual symptoms.

Imaging findings are variable and nonspecific. AT/RT have iso-intense to hyperintense T2 signal, and enhance with contrast administration. (7) Histologically, these tumors are heterogenous lesions, composed of bizarre eosinophilic cells with eccentric nuclei, and mixed features of rhabdoid, neuroectodermal, and mesenchymal cells. (7)

Loss of INI1 staining due to SMARCB1 mutations is considered sufficient for diagnosis, which appears to be the most consistent mutation in Adult AT/RR. (7) Alternatively, inactivation of BRG1 due to mutation of SMARCA4 is rarely recognized if INI1 expression is intact. (13) Nakata et al studied the molecular status of the INI1/SMARCB1 gene in a series of adult sellar AT/RT. (12) Compound heterozygous mutations were present in 57% of cases of sellar AT/RT, in contrast to pediatric AT/RT where such mutations are rare. (12,14) In addition, there was a significant difference in their prevalence between sellar AT/RT and conventional AT/RT. On the other hand, homozygous deletion of INI1 gene was not reported in sellar AT/RT cases despite being a common mutation in typical AT/RT. (6) Those observations may indicate that sellar AT/RT represent unique variant of AT/RT with different demographical, molecular, and clinical characteristics.

Sellar AT/RT cases appear to have more favorable outcome than conventional AT/RT. (5,15) The estimated median overall survival of sellar AT/RT is 30 months, with 1-year survival of 76.7%, compared to 11 to 14 months for conventional AT/RT. (11,16) Achieving gross total resection was a determinant for favorable outcome in pediatric. (17) Yet, there was no survival benefit seen for gross total resection in adult AT/RT. (18) Receiving chemotherapy and radiotherapy was significantly associated with better survival compared with radiotherapy only or no adjuvant therapy at all. (5,18) Adjuvant therapy protocols varied drastically in the literature, with data mostly being extrapolated from pediatric literature. Slavic et al (9) developed an intensive 9-week course of a dose-dense regimen, augmented with intrathecal therapy followed by high-dose chemotherapy and radiotherapy for pediatric AT/RT. This protocol achieved a 5-year overall survival rate of 100% and a 5-year event-free survival rate of 88.9% in nine cases of AT/RT with and without disseminated disease.

Sellar AT/R is extremely rare in an adult male. We report the third case in the literature. Thus disputing the belief that it is a female-exclusive disease. Nonetheless, Sellar AT/RT poses a unique entity that mandates further research and understanding.

ACKNOWLEDGEMENTS: None.

Reference:

1. Almalki MH, Alrogi A, Al-Rabie A, Al-Dandan S, Altwairgi A, Orz Y. Atypical Teratoid/Rhabdoid Tumor of the Sellar Region in an Adult With Long Survival: Case Report and Review of the Literature. *J Clin Med Res* [Internet]. 2017 [cited 2020 Mar 30];9(3):216–20. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/28179970><http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC5289142><http://www.jocmr.org/index.php/JOCMR/article/view/2922>
2. Biegel JA. Molecular genetics of atypical teratoid/rhabdoid tumor. Vol. 20, *Neurosurgical focus*. Neurosurg Focus; 2006.
3. Burger PC, Yu IT, Tihan T, Friedman HS, Strother DR, Kepner JL, et al. Atypical teratoid/rhabdoid tumor of the central nervous system: A highly malignant tumor of infancy and childhood frequently mistaken for medulloblastoma: A Pediatric Oncology Group study. *Am J Surg Pathol*. 1998 Sep;22(9):1083–92.
4. Chan V, Marro A, Max Findlay J, Schmitt LM, Das S. A systematic review of atypical teratoid rhabdoid tumor in adults. Vol. 8, *Frontiers in Oncology*. Frontiers Media S.A.; 2018.
5. Dardis C, Yeo J, Milton K, Ashby LS, Smith KA, Mehta S, et al. Atypical teratoid rhabdoid tumor: Two case reports and an analysis of adult cases with implications for pathophysiology and treatment. *Front Neurol*. 2017 Jun 20;8(JUN).
6. Horn M, Schlote W, Lerch KD, Steudel WI, Harms D, Thomas E. Malignant rhabdoid tumor: primary intracranial manifestation in an adult. *Acta Neuropathol*. 1992 Jul;83(4):445–8.
7. Isikay I, Hanalioglu S, Basar I, Narin F, Bilginer B. Survival benefit with gross total resection and adjuvant radiotherapy in childhood atypical teratoid/rhabdoid tumors: Results of a single-center cohort of 27 cases. *Turk Neurosurg* [Internet]. 2019 [cited 2021 Jun 7];29(5):689–97. Available from: <https://pubmed.ncbi.nlm.nih.gov/30875078/>
8. Liu F, Fan S, Tang X, Fan S, Zhou L. Adult Sellar Region Atypical Teratoid/Rhabdoid Tumor: A Retrospective Study and Literature Review. *Front Neurol* [Internet]. 2020 Dec 15 [cited 2021 Jun 7];11:604612. Available from: [/pmc/articles/PMC7769810/](https://pubmed.ncbi.nlm.nih.gov/30875078/)
9. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK. The 2007 WHO classification of tumours of the central nervous system. International Agency for Research on Cancer (IARC) 69372 Lyon Cedex 08, France; 2016.
10. Montgomery P, Kuhn JP, Berger PE. Rhabdoid tumor of the kidney: A case report. *Urol Radiol A J diagnostic imaging*. 1985;7(1):42–4.
11. Nakata S, Nobusawa S, Hirose T, Ito S, Inoshita N, Ichi S, et al. Sellar Atypical Teratoid/Rhabdoid Tumor (AT/RT). *Am J Surg Pathol*. 2017 Jul;41(7):932–40.
12. Nishikawa A, Ogiwara T, Nagm A, Sano K, Okada M, Chiba A, et al. Atypical teratoid/rhabdoid tumor of the sellar region in adult women: Is it a sex-related disease? Vol. 49, *Journal of Clinical Neuroscience*. Churchill Livingstone; 2018. p. 16–21
13. Paolini MA, Kipp BR, Sukov WR, Jenkins SM, Fritcher EGB, Aranda D, et al. Sellar Region Atypical Teratoid/Rhabdoid Tumors in Adults: Clinicopathological

Characterization of Five Cases and Review of the Literature. Available from:

<https://academic.oup.com/jnen/article/77/12/1115/5116242>

14. Rickert CH, Paulus W. Epidemiology of central nervous system tumors in childhood and adolescence based on the new WHO classification. *Child's Nerv Syst.* 2001;17(9):503–11.
15. Schneppenheim R, Frühwald MC, Gesk S, Hasselblatt M, Jeibmann A, Kordes U, et al. Germline Nonsense Mutation and Somatic Inactivation of SMARCA4/BRG1 in a Family with Rhabdoid Tumor Predisposition Syndrome. *Am J Hum Genet.* 2010 Feb;86(2):279–84.
16. Schrey D, Carceller Lechón F, Malietzis G, Moreno L, Dufour C, Chi S, et al. Multimodal therapy in children and adolescents with newly diagnosed atypical teratoid rhabdoid tumor: individual pooled data analysis and review of the literature. *J Neurooncol.* 2016 Jan;126(1):81–90.
17. Slavic I, Chocholous M, Leiss U, Haberler C, Peyrl A, Azizi AA, et al. Atypical teratoid rhabdoid tumor: improved long-term survival with an intensive multimodal therapy and delayed radiotherapy. The Medical University of Vienna Experience 1992-2012. *Cancer Med [Internet].* 2014 Feb 1 [cited 2020 Nov 10];3(1):91–100. Available from: /pmc/articles/PMC3930393/?report=abstract
18. Torchia J, Golbourn B, Feng S, Ho KC, Sin-Chan P, Vasiljevic A, et al. Integrated (epi)-Genomic Analyses Identify Subgroup-Specific Therapeutic Targets in CNS Rhabdoid Tumors. *Cancer Cell.* 2016 Dec;30(6):891–908.

Key words:

Atypical teratoid/ rhabdoid tumor, AT/RT, sellar lesion, Inactivation of SMARCB1, SMARCB1




Figure 1: A: MRI brain with contrast showing sellar lesion with suprasellar extension and extension inferiorly to the sphenoid sinus. B: Post gadolinium study showed the lesion to be enhancing in its periphery only with mild heterogeneous enhancement in the center




Figure 2: MRI brain with contrast showing Slight interval progression of lesion size with heterogeneous texture/enhancement and ill-defined margins. And development of subacute intraventricular hemorrhage predominantly involving third ventricle.




Figure 3: Histopathological examination: A: H&E slide shows hemorrhagic and necrotic neoplasm with focal papillary architecture. B: The tumor is composed of cells with round nuclei, prominent nucleoli and scant cytoplasm. C: Immunohistochemical stain (EMA), positive in the tumor cells. D: Immunohistochemical stain (INI-1), loss of expression in the tumor cells and retention in the internal positive controls including endothelial cells. E: (Ki67) proliferation index, focally elevated.